Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2005-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation

NCT00153140

Constipation

COMPLETED PHASE4

The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia

NCT00277550

Constipation and Dyspepsia

WITHDRAWN PHASE4

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation

NCT00511771

Irritable Bowel Syndrome With Constipation Chronic Idiopathic Constipation

NO_LONGER_AVAILABLE

Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients

NCT00348634

Chronic Constipation

TERMINATED PHASE4

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

NCT00365820

Constipation

TERMINATED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tegaserod and Polyethylene Glycol 3350

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females aged 18 to 64 years of age
* Patients with constipation as defined by the Rome II criteria

Exclusion Criteria

* Patients who have been previously been treated with tegaserod and/or PEG 3350
* Evidence of cathartic colon or a history of laxative abuse or laxative dependence
* History of fecal impaction which necessitated surgical intervention
* Patients with clinically significant abnormal TSH levels at screening
* Women who are pregnant or breast feeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No